Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD2 x IL2RG bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
CD2 x IL2RG bispecific antibody is a preclinical-stage bispecific antibody being developed by Xencor for the treatment of graft-versus-host disease (GVHD) and other autoimmune and inflammatory diseases. The antibody is engineered with blocking arms targeting both CD2 and the interleukin-2 receptor subunit gamma (IL2RG, also known as the common gamma chain or γc). By dual-targeting these pathways, the bispecific antibody selectively blocks IL2RG-mediated γc cytokine signaling (which regulates lymphocyte survival and activation) and CD2-dependent co-stimulation on CD2-positive lymphocytes, such as T cells and natural killer (NK) cells. This dual mechanism provides synergistic modulation of lymphocyte activation, leading to potent suppression of effector activity and prevention of GVHD while minimizing systemic immunosuppression.
- Other names
- CD2 x IL-2RG bispecific antibodiesCD-2 x IL-2RG bispecific antibodiesCD 2 x IL-2RG bispecific antibodiesCD2 x IL-2RG bispecific antibodyCD-2 x IL-2RG bispecific antibodyCD 2 x IL-2RG bispecific antibodyCD2 x IL2RG bispecific antibodiesCD-2 x IL2RG bispecific antibodiesCD 2 x IL2RG bispecific antibodiesCD2 x IL2RG bispecific antibodyCD-2 x IL2RG bispecific antibodyCD 2 x IL2RG bispecific antibodyCD2/IL-2RG bispecific antibodyCD2/IL2RG bispecific antibody
02
Targets
CD2 (T-cell Surface Antigen CD2)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on CD2 x IL2RG bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD2 x IL2RG bispecific antibody.